{"id":"5c161dcf2bf8","type":"article","url":"https://hartvaat.nl/2022/08/01/empagliflozine-vermindert-nierletselmarkers-bij-acuut-hartfalen/","title":"Empagliflozine vermindert nierletselmarkers bij acuut hartfalen","title_en":"Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["abelacimab","acuut-hartfalen","bisoprolol","canagliflozine","complementremmers","cystatine-c","dapagliflozine","empagliflozine","emperor-trials","ezetimibe","hfmref","hfpef","hfref","ijzersuppletie","nt-probnp","primaire-preventie","sglt2-remmers"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13955","source_url":"https://doi.org/10.1002/ehf2.13955","authors":["Kirsten Thiele","Matthias Rau","Niels-Ulrik Korbinian Hartmann","Marcus Möller","Julia Möllmann","Joachim Jankowski","András P Keszei","Michael Böhm","Jürgen Floege","Nikolaus Marx","Michael Lehrke"],"significance":6,"published":"2022-08-01","source_date":"2022-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This exploratory study showed that empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure, suggesting renal protective effects of SGLT2 inhibition despite initial eGFR dip.","created":"2026-07-03T10:29:51Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Exploratieve studie toonde dat empagliflozine bij acuut gedecompenseerd hartfalen markers van acute nierschade verminderde, ondanks de verwachte initiële eGFR-daling. Dit ondersteunt de nierbeschermende werking van SGLT2-remmers bij kritisch zieke hartfalenpatiënten.","abstract_original":"AIMS: In this prospective, placebo-controlled, double-blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patients with acute decompensated heart failure (HF). METHODS AND RESULTS: Patients with acute decompensated HF with or without diabetes were randomized to empagliflozin 10 mg or placebo for 30 days. Haemodynamic, laboratory, and urinary parameters were assessed after 6 h, 1 day, 3 days, 7 days, and 30 days of treatment. Median time between hospital admission and randomization was 72 h. Baseline characteristics were not different in the empagliflozin (n = 10) and placebo (n = 9) groups. Empagliflozin led to a significant increase in urinary glucose excretion throughout the study (baseline: 37 ± 15 mg/24 h; Day 1: 14 565 ± 8663 mg/24 h; P = 0.001). Empagliflozin did not affect the primary endpoint of cardiac index or on systemic vascular resistance index at any time point. However, empagliflozin significantly reduced parameters of AKI (urinary TIMP-2 and IGFBP7 by NephroCheck® as indicators of tubular kidney damage), which became significant after 3 days of treatment [placebo: 1.1 ± 1.1 (ng/mL)2 /1000; empagliflozin: 0.3 ± 0.2 (ng/mL)2 /1000; P = 0.02] and remained significant at the 7 day time point [placebo: 2.5 ± 3.8 (ng/mL)2 /1000; empagliflozin: 0.3 ± 0.2 (ng/mL)2 /1000; P = 0.003]. CONCLUSIONS: In this study, empagliflozin treatment did not affect haemodynamic parameters but significantly reduced markers of tubular injury in patients with acute decompensated HF."}